Skip To Main Content
Mike Hollan on Muck Rack

Mike Hollan

Verified
New York
As seen in: MJH Life Sciences, Pharmaceutical Executive, Yahoo News, Fox News, New York Post, News.com.au, Yahoo Finance, MarketWatch, Fox Business, Yahoo, CBR, Screen Rant and
Lifestyle writer for Fox News. Dog owner. I don't know what else to put here.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mike

Contact Mike, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

U.S. Rare Disease Biotech Investing Rises After FDA’s PRV Program Renewal: Report

|
By Mike Hollan Verified, Tyler Seville, Joseph Morwald
| EIN News
Renewal of FDA's Priority Review Voucher program is driving a rebound in U.S. rare disease biotech investment, while the UK continues to lag. Investment in rare disease biotechs is picking up in the U.S. following the renewal of FDA's Priority Review Voucher (PRV) program, according to SynaptixBio.
Open in Who Shared View Duplicates (2) Issue with article?

Reshoring Pharma and Biotech Manufacturing Ahead of This Summer’s Tariff Deadlines: Q&A with Ryan Last

|
By Mike Hollan Verified, Ryan Last, Realistic Timelines
| EIN News
The Troutman Pepper Locke senior associate discusses strategies for pharma and biotech companies to implement ahead of the July 31st tariff deadlines. In April of this year, President Trump announced plans to impose 100% tariffs on branded pharmaceutical imports. At the time, he set a deadline of July 31, 2026, for major pharmaceutical companies to negotiate onshoring agreements (which would reduce the tariffs to 20%).
Open in Who Shared Issue with article?

Additive Manufacturing's Application in Pharma and Biotech

|
By Nicholas Jacobus, Brian Hilberdink, Mike Hollan Verified
| EIN News
Kyle Smith, president and COO of Aprecia, discusses how additive manufacturing allows for the rapid development and manufacturing of a variety of dosage forms. Additive manufacturing allows pharma and biotech companies to take advantage of 3D printing technology to produce medications in a variety of dosages while achieving reliably consistent results. A major benefit of the process is the speed in which its able to produce a prototype and then shift to broad manufacturing.
Open in Who Shared Issue with article?
See all 4,138 licensed articles (5,261 Total)